Whalesbook
Akums Drugs & Pharmaceuticals Ltd. has secured a significant upgrade in its credit profile, with ICRA reaffirming its '[ICRA]AA (Stable)' rating for the company's long-term bank facilities and assigning a strong '[ICRA]A1+' rating to its proposed commercial paper programme. The total value of rated facilities has been expanded to ₹285 crore. This positive credit assessment is further supported by a substantial EUR 200 million contract from a European customer.
Credit Rating Action and Expansion
ICRA's decision to reaffirm the '[ICRA]AA (Stable)' rating underscores Akums' robust financial health and its capacity to meet long-term debt obligations. Simultaneously, the assignment of the '[ICRA]A1+' rating signals high confidence in the company's ability to manage its short-term liabilities, a crucial factor for operational flexibility and commercial paper issuance. The enhancement of the total rated amount from ₹145 crore to ₹285 crore reflects the expanded scale of the company's financing needs and its established credit standing.
Strategic Importance of Ratings and Contract
Strong credit ratings are vital for pharmaceutical companies like Akums, as they can lead to lower borrowing costs and improved access to capital markets for future expansion or operational needs. The '[ICRA]A1+' rating, in particular, is a key indicator of financial strength and liquidity for short-term funding.
The newly secured EUR 200 million contract with a European client is a significant development. It not only diversifies Akums' revenue streams but also provides strong visibility for future earnings, with sales expected to commence from calendar year 2027. The company has already received an upfront payment of EUR 100 million, which has substantially strengthened its liquidity position.
Financial Foundation and Recent Developments
Akums, a leading contract development and manufacturing organization (CDMO), has consistently worked to strengthen its financial standing. The company's long-term rating had already been upgraded to '[ICRA]AA(Stable)' in October 2024.
Earlier in August 2024, Akums completed an Initial Public Offering (IPO) that raised approximately ₹680 crore. The proceeds from this IPO were primarily used to reduce existing debt and bolster the company's balance sheet.
This latest rating action and the large European contract build upon this foundation of financial improvement and strategic growth.
Impact of Enhanced Creditworthiness
The improved credit ratings are expected to enable Akums to secure future borrowings on more favorable terms. The '[ICRA]A1+' rating provides a clear pathway for efficient short-term financing options, such as issuing commercial papers.
The substantial European contract is poised to be a key driver of top-line growth, diversifying Akums' customer base and geographical presence. The robust liquidity, bolstered by the substantial upfront payment, offers a solid cushion to support planned capital expenditures.
Potential Risks and Challenges
Despite the positive developments, Akums faces several risks. Profitability could be impacted by competitive pressures and volatility in raw material prices, especially within the trade generics and API segments.
The company is also exposed to regulatory risks, including potential government price controls like the National List of Essential Medicines (NLEM) and product liability issues.
An ongoing Income Tax investigation, initiated in January 2025, poses a potential financial uncertainty, with its ultimate implications still unascertainable. While past summonses from the Directorate of Enforcement (ED) were noted, no adverse actions have been reported to date. Additionally, a subsidiary faced a ₹1.80 crore penalty in December 2025 for invoicing errors, highlighting the need for ongoing compliance vigilance.
Comparison with Industry Peers
Akums operates in the competitive CDMO sector alongside established players like Divi's Laboratories and Sun Pharmaceutical Industries.
A key financial metric for Akums is its notably low debt-to-equity ratio of 0.03 as of FY2024, indicating strong financial leverage management when compared to many industry peers. While some competitors, such as Divi's Laboratories, may hold higher ratings (e.g., AAA), Akums' '[ICRA]AA' rating still signifies strong credit quality within its operational segment.
Key Financial Metrics
As of September 30, 2025:
- Total Debt (including lease liabilities) stood at ₹90.3 crore.
- Cash and Cash Equivalents were ₹1,654.4 crore.
The long-term contract with the European customer is valued at EUR 200 million, approximately ₹1,760 crore.
Future Focus Areas
Investors and analysts will be tracking several key developments:
- The successful execution and commencement of sales for the EUR 200 million European contract, expected from CY2027.
- Updates regarding the ongoing Income Tax investigation and any potential financial repercussions.
- ICRA's future credit rating reviews and any potential adjustments.
- The company's planned capital expenditure of ₹250 crore annually for FY2026-FY2028, particularly for the Zambia facility.
- Developments concerning the subsidiary's penalty and the implementation of enhanced compliance measures.